Diabetes

The experimental drug CMX-2043 protected heart muscle from stenting but it has shown no increased protection in kidneys.

Concerns raised regarding a three-fold rise in the cost of insulin as other diabetes drugs remained stable.

People from poor or middle-income households with conditions such as diabetes or asthma face greater risk for serious mental illness.

People with difficulty repairing damaged DNA develop diabetes more rapidly when beta cells are met with cellular stress.

All diabetic neuropathies increase risk of all-cause death and adversely affect quality of life.

The FDA has announced that it is updating the labels of several type 2 diabetes medications to warn patients and providers of an increased heart failure risk associated with the drugs' use.

Administering type 2 diabetes drugs to patients with maturity-onset diabetes of the young can cause harm.

Mindful exercise, eating, and stress-reducing practices could help obese patients reduce their diabetes risk.

Metformin use is associated with a reduced risk of glaucoma development among diabetics.

Race and income level found to influence reaction to drug safety alerts.

FDA needs to consider patient demographics to improve the public's response to drug safety warnings.

Maturity-onset diabetes of the young is a rare form of diabetes caused by a range of genetic mutations that interrupt beta cell function.

Researchers compare once-daily injection of degludec and liraglutide versus once-daily injection of glargine.

Pharmacists should be aware of the latest drug trend report from the nation's largest pharmacy benefits manager to better inform patients of any shifts in pricing.

One of the most under-recognized and under-addressed barriers to safe and effective care is low vision.

Susan Cornell, PharmD, CDE, FAPhA, FAADE, offers tips for how pharmacists can monitor for hypoglycemia in type 2 diabetics on second-line therapies.

Pharmacists should keep an eye out for patients with diabetes taking pravastatin and paroxetine concomitantly, as this medication combination could be deadly.

Susan Cornell, PharmD, CDE, FAPhA, FAADE, outlines some strategies for pharmacists tasked with selecting the most appropriate second-line therapy for their patients with type 2 diabetes.

Obese patients who are able to lose 5% of their bodyweight may lower their risk for type 2 diabetes.

Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.

Susan Cornell, PharmD, CDE, FAPhA, FAADE, discusses the contraindications and adverse effects pharmacists should consider when recommending antidiabetic agents.

Jennifer Costello, PharmD, BCPS, BC-ADM, discusses several new and emerging therapies for type 2 diabetes and glycemic control.

Pharmacists can positively influence the primary care management of diabetes.

While diabetes is a growing national health threat, it's especially prevalent in Mississippi, where 1 in 8 residents are diabetic.

Fixed-ratio combination of basal insulin glargine 1and GLP-1 receptor agonist lixisenatide shpws promise in adults with type 2 diabetes.